Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
Launched by DONG-A ST CO., LTD. · Apr 27, 2016
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
When the future evogliptin be administered to liver dysfunction patients, to investgate whether dose adjustment is necessary.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \<Hepatic Dysfunction\>
- • At least 6 months with chronic liver disease (Regardless of cause hepatic dysfunction)
- • Child-Pugh A or B
- • \<Healthy Control\>
- • Subject has the following conditions: age ± 5 years, BMI ± 20%, same sex of each matched hepatic dysfunction subject
- Exclusion Criteria:
- • \<Hepatic Dysfunction\>
- • Child-Pugh C
- • History of Liver transplant
- • \<Healthy Control\>
- • History of chronic liver disorders
- • Pregnant or lactating women
About Dong A St Co., Ltd.
Dong-A ST Co., Ltd. is a leading pharmaceutical and biotechnology company based in South Korea, dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a robust portfolio spanning various therapeutic areas, including neurology, oncology, and cardiovascular health, Dong-A ST is committed to advancing healthcare through cutting-edge clinical research and high-quality products. The company emphasizes a patient-centered approach, collaborating with global partners to enhance treatment options and improve health outcomes worldwide. Through its rigorous clinical trials and commitment to scientific excellence, Dong-A ST strives to contribute meaningfully to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials